» Articles » PMID: 30547005

Higher Hemoglobin A1C and Atherogenic Lipoprotein Profiles in Children and Adolescents with Type 2 Diabetes Mellitus

Overview
Specialty Endocrinology
Date 2018 Dec 15
PMID 30547005
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Significant knowledge gaps exist regarding lipoprotein profiles in children with type 2 diabetes mellitus (T2DM). The primary objective was to analyze the type and nature of lipoprotein abnormalities present in children with T2DM and to identify determinants of adverse lipoprotein profiles. The secondary objective was to assess associations with elevated glycated hemoglobin (HbA1C), i.e., <8% vs. ≥8.0% and pediatric dyslipidemias in the setting of T2DM.

Methods: This retrospective chart review included children with T2DM who had undergone lipoprotein analysis and were not on lipid lowering medications (n = 93).

Results: The participants (mean age 15.2 ± 2.7y) were 71% female and 78% African American (AA). Adjusted for age, sex, and race, BMI z-score was positively associated with LDL-pattern B (pro-atherogenic profile with small dense LDL particles) (P = 0.01), and negatively associated with total HDL-C (P = 0.0003). HbA1C was robustly positively associated with the LDL-C, apoB and LDL pattern B (all P < 0.001). Patients with an HbA1C >8% had significantly higher total cholesterol (191.4 vs. 158.1 mg/dL,  = 0.0004), LDL-C (117.77 vs. 92.3 mg/dL,  = 0.002), apoB (99.5 vs. 80.9 mg/dL,  = 0.002), non-HDL-C (141.5 vs. 112.5,  = 0.002), and frequency of LDL pattern B (57% vs. 20%,  = 0.0008).

Conclusion: HbA1C and BMI were associated with adverse lipoprotein profiles, and may represent two major modifiable cardiovascular risk factors in the pediatric T2DM population. Patients with an HbA1C higher than 8.0% had significantly worse atherogenic lipid profile, i.e., higher LDL-C, non-HDL-C, apoB and LDL pattern B, suggesting adequate glycemia may improve adverse lipoprotein profiles.

Citing Articles

The Relationship Between Lipoproteins and Insulin Sensitivity in Youth With Obesity and Abnormal Glucose Tolerance.

Chung S, Katz L, Stettler-Davis N, Shults J, Sherman A, Ha J J Clin Endocrinol Metab. 2022; 107(6):1541-1551.

PMID: 35240684 PMC: 9113822. DOI: 10.1210/clinem/dgac113.


Effects of High-Intensity Interval Training and Moderate-Intensity Continuous Training on Cardiometabolic Risk Factors in Overweight and Obesity Children and Adolescents: A Meta-Analysis of Randomized Controlled Trials.

Cao M, Tang Y, Li S, Zou Y Int J Environ Res Public Health. 2021; 18(22).

PMID: 34831659 PMC: 8623248. DOI: 10.3390/ijerph182211905.


Glycemic control is associated with dyslipidemia over time in youth with type 2 diabetes: The SEARCH for diabetes in youth study.

Brady R, Shah A, Jensen E, Stafford J, DAgostino Jr R, Dolan L Pediatr Diabetes. 2021; 22(7):951-959.

PMID: 34363298 PMC: 8530941. DOI: 10.1111/pedi.13253.


Prevalence of Hypertension and Albuminuria in Pediatric Type 2 Diabetes: A Systematic Review and Meta-analysis.

Cioana M, Deng J, Hou M, Nadarajah A, Qiu Y, Chen S JAMA Netw Open. 2021; 4(4):e216069.

PMID: 33929524 PMC: 8087958. DOI: 10.1001/jamanetworkopen.2021.6069.


Dyslipidemia in Pediatric Type 2 Diabetes Mellitus.

Sunil B, Ashraf A Curr Diab Rep. 2020; 20(10):53.

PMID: 32909078 PMC: 7481147. DOI: 10.1007/s11892-020-01336-6.


References
1.
Mackey R, Mora S, Bertoni A, Wassel C, Carnethon M, Sibley C . Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis. Diabetes Care. 2015; 38(4):628-36. PMC: 4370328. DOI: 10.2337/dc14-0645. View

2.
Brown W, Sacks F, Sniderman A . JCL roundtable: Apolipoproteins as causative elements in vascular disease. J Clin Lipidol. 2015; 9(6):733-740. DOI: 10.1016/j.jacl.2015.10.003. View

3.
Copeland K, Zeitler P, Geffner M, Guandalini C, Higgins J, Hirst K . Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2010; 96(1):159-67. PMC: 3038479. DOI: 10.1210/jc.2010-1642. View

4.
Kulkarni K . Cholesterol profile measurement by vertical auto profile method. Clin Lab Med. 2006; 26(4):787-802. DOI: 10.1016/j.cll.2006.07.004. View

5.
Brunzell J, Davidson M, Furberg C, Goldberg R, Howard B, Stein J . Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008; 31(4):811-22. DOI: 10.2337/dc08-9018. View